tirzepatide head to head semaglutide Head-to-Head: Outperforms Tirzepatide vs Semaglutide: The Head

An InBody scan at 46 weeks identifies early disproportionate lean mass loss before it becomes clinically significant, allowing dietary intervention before it progresses

The LEADER trial showed that liraglutide reduced the risk of major cardiovascular events in people with type 2 diabetes.[4] Soon after, SUSTAIN-6 demonstrated similar benefits with semaglutide.[5] Then came REWIND, which suggested that cardiovascular protection could extend even to patients without established cardiovascular disease.[6] The SELECT trial made headlines because it showed cardiovascular benefits in people with overweight or obesity who did not have diabetes, a finding that challenged long-held assumptions about who might benefit from these medicines.[7] Most recently, an international trial called SOUL, which tested an oral form of semaglutide, included 788 Indian patients across 32 centres

Estos medicamentos tienen el potencial de producir una prdida de peso considerable, especialmente en el primer ao, afirm Juan Franco, investigador de la Universidad Heinrich Heine de Dsseldorf y autor de una de las revisiones

The FDA issued this alert saying counterfeits have been found in the US drug supply chain